Concepedia

Stephen Donahue

SD

Statistics

Publications

19

Citations

1.3K

H-Index

14

Active since

1989

Affiliations

Regeneron (United States)(Current)

Sanofi (France)

Tufts University

Louisville Metabolic and Atherosclerosis Research Center

Université de Montréal

Stephen Donahue is an author at Regeneron (United States) specializing in pharmacology, pharmacy, and medicine.

Publications per year

1989–2025

19

Publications

19

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial

Harold Bays, Daniel Gaudet, Robert Weiss et al. · The Journal of Clinical Endocrinology & Metabolism · 2015 · 221 citations · Full text

, , +17

Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force

Bruno Vellas, Roger A. Fielding, Cynthia Bens et al. · The Journal of Frailty & Aging · 2018 · 190 citations · Full text

, , +9

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

Michel Farnier, Peter J.H. Jones, Randall Severance et al. · Atherosclerosis · 2015 · 187 citations · Full text

, , +17

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia

Dirk Blom, Mariko Harada‐Shiba, Paolo Rubba et al. · Journal of the American College of Cardiology · 2020 · 165 citations · Full text

, , +17

Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19*

Stephen Donahue, David A. Flockhart, Jae-Wook Ko · Clinical Pharmacology & Therapeutics · 1997 · 73 citations

, , +16

1–5 of 19